VYNE Therapeutics Inc. (VYNE) — Financial statements
Income statement, balance sheet, and cash flow for VYNE Therapeutics Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.57↑13.8% | 0.50↑18.2% | 0.42↓11.1% | 0.48↓48.8% | 0.93 | |
| Cost of Revenue | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.55↑9.2% | 0.50↑18.2% | 0.42↓11.1% | 0.48↓48.8% | 0.93 | |
| Operating Expenses | ||||||
| R&D Expenses | 19↓37.8% | 31↑89.8% | 16↓11.3% | 18↓5.9% | 20 | |
| General & Administrative Expenses | 11↓16.0% | 13↓1.4% | 13↓18.4% | 16 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 11↓16.0% | 13↓1.4% | 13↓18.4% | 16↓19.3% | 20 | |
| Other Expenses | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 30↓31.4% | 44↑48.7% | 30↓14.6% | 35↓12.7% | 40 | |
| Total Costs & Expenses | 30↓31.3% | 44↑48.7% | 30↓14.6% | 35↓12.7% | 40 | |
| Operating Results | ||||||
| Operating Income | -30↑31.8% | -44↓49.1% | -29↑14.7% | -34↑11.9% | -39 | |
| Depreciation & Amortization | 0.00↓100.0% | 0.00 | 0.00↓100.0% | 0.07↓33.9% | 0.11 | |
| EBITDA | -27↑38.7% | -44↓49.1% | -29↑14.5% | -34↑11.8% | -39 | |
| EBIT | -27↑38.7% | -44↓49.1% | -29↑14.7% | -34↑11.9% | -39 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00 | 0.00 | 0.00 | 0.00↑100.0% | -6 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 6 | |
| Non-Operating Income | -3 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 3↓21.3% | 4↑176.6% | 1↑281.8% | 0.36↑107.5% | -5 | |
| Income Before Tax | -27↑32.8% | -40↓42.8% | -28↑17.9% | -34↑22.5% | -44 | |
| Income Tax Expense | 0.00↑0.0% | 0.00 | 0.00↓100.0% | 0.01↓97.1% | 0.45 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -27↑32.8% | -40↓42.8% | -28↑17.9% | -34↑23.2% | -44 | |
| Net Income from Discontinued Operations | 0.25↑1037.0% | -0.03↑95.3% | -0.58↓105.4% | 11↑136.9% | -29 | |
| Net Income | -26↑33.5% | -40↓40.0% | -28↓22.6% | -23↑68.3% | -73 | |
| Bottom-Line Net Income | -26↑33.5% | -40↓40.0% | -28↓22.6% | -23↑47.5% | -44 | |
| EPS (Basic) | -0.62↑34.0% | -0.94↑66.1% | -2.77↑74.0% | -10.65↑58.5% | -25.65 | |
| EPS (Diluted) | -0.62↑34.0% | -0.94↑66.1% | -2.77↑74.0% | -10.65↑58.5% | -25.65 | |
| Weighted Average Shares | 43↑0.4% | 43↑314.6% | 10↑222.4% | 3↑11.4% | 3 | |
| Weighted Average Diluted Shares | 43↑0.4% | 43↑314.6% | 10↑222.4% | 3↑11.4% | 3 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.